Prehospital Initiation of Magnesium Sulfate in Patients with Acute Intracerebral Hemorrhage (S39.003)

Conclusions: Prehospital initiation permitted start of Mg therapy within the first 45 minutes of symptom onset in over half of patients, but did not alter rates of clinical deterioration in the first hours or disability at 3 months. Study Supported by NIH-NINDS Award U01 NS 44364Disclosure: Dr. Sanossian has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc. as a speakers bureau participant. Dr. Starkman has received research support from the National Institutes of Health, Lundbeck Research USA, Inc., Mitsubishi Tanabe Pharma, and Neurobiological Technologies, Inc. Dr. Liebeskind has received personal compensation for activities with Stryker and Covidien as a consultant. Dr. Hamilton has nothing to disclose. Dr. Eckstein has nothing to disclose. Dr. Stratton has nothing to disclose. Dr. Pratt has nothing to disclose. Dr. Conwit has nothing to disclose. Dr. Sung has received personal compensation for activities with Johnson & Johnson and Haemonetics as a speakers bureau participant. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, eV3, Talecris Biotherapeutics Inc., and PhotoThera, Inc.

Source: Neurology - April 8, 2015 Category: Neurology Authors: Sanossian, N., Starkman, S., Liebeskind, D., Hamilton, S., Eckstein, M., Stratton, S., Pratt, F., Conwit, R., Sung, G., Saver, J. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage Source Type: research